Limited coverage drugs – fluticasone furoate in combination with umeclidinium and vilanterol

Last updated on January 17, 2024

Special Authority requests can now be submitted online. It's simple and quick!

Generic name	fluticasone furoate-umeclidinium-vilanterol
Strength	fluticasone furoate 100 mcg/umeclidinium 62.5 mcg/vilanterol 25 mcg
Form	dry powder for oral inhalation

Special Authority criteria	Approval period
Diagnosis of moderate to very severe¹chronic obstructive pulmonary disease (COPD) where spirometry measures are as follows: A post-bronchodilator fixed ratio of forced expiratory volume in 1 second (FEV₁)/forced vital capacity (FVC) < 0.70 AND A post-bronchodilator FEV₁ < 80% predicted AND Who have a history of exacerbations as follows: History of ≥ 2 moderate exacerbations defined as requiring a prescribed antibiotic and/or using systemic glucocorticoids in the previous 12 months OR History of ≥ 1 severe exacerbation defined as requiring a hospital admission or emergency department visit in the previous 12 months AND Inadequate response after a minimum 6-month trial of either a combination of long-acting muscarinic receptor antagonist (LAMA) and long-acting beta agonist (LABA) OR a combination of inhaled corticosteroids (ICS) and LABA	Indefinite

Special Authority criteria

Approval period

Diagnosis of moderate to very severe¹chronic obstructive pulmonary disease (COPD) where spirometry measures are as follows:

A post-bronchodilator fixed ratio of forced expiratory volume in 1 second (FEV₁)/forced vital capacity (FVC) < 0.70

AND

A post-bronchodilator FEV₁ < 80% predicted

AND

Who have a history of exacerbations as follows:

History of ≥ 2 moderate exacerbations defined as requiring a prescribed antibiotic and/or using systemic glucocorticoids in the previous 12 months

History of ≥ 1 severe exacerbation defined as requiring a hospital admission or emergency department visit in the previous 12 months

AND

Inadequate response after a minimum 6-month trial of either

a combination of long-acting muscarinic receptor antagonist (LAMA) and long-acting beta agonist (LABA)

a combination of inhaled corticosteroids (ICS) and LABA

Indefinite

Notes

Moderate to very severe COPD is defined as follows:
- Moderate COPD is defined as 50% ≤ FEV₁ < 80% predicted
- Severe COPD is defined as 30% ≤ FEV₁ < 50% predicted
- Very severe COPD is defined as FEV₁ < 30% predicted

Practitioner exemptions

Respirologists are invited to apply for a Collaborative Prescribing Agreement (CPA).
Respirologists who already have a CPA for budesonide-gylcopyrronium-formoterol (Breztri Aerosphere) automatically have a CPA for Trelegy Ellipta.

Special notes

In remote areas, where spirometry access is limited, spirometry measurements are to be provided within 6 months.

Special Authority request form(s)

Log in to eForms
HLTH 5362 - COPD Form (PDF, 100KB)

Did you find what you were looking for?

The B.C. Public Service acknowledges the territories of First Nations around B.C. and is grateful to carry out our work on these lands. We acknowledge the rights, interests, priorities, and concerns of all Indigenous Peoples - First Nations, Métis, and Inuit - respecting and acknowledging their distinct cultures, histories, rights, laws, and governments.

More topics

Limited coverage drugs – fluticasone furoate in combination with umeclidinium and vilanterol

Notes

Practitioner exemptions

Special notes

Special Authority request form(s)